MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 145867 | Name: Citramide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Citramide is a synthetic chemical compound commonly used as a surfactant and emulsifier in various industrial applications, particularly in cosmetics and personal care products. It helps improve the stability and texture of formulations by reducing surface tension and allowing ingredients to mix more effectively. The mechanism of citramide involves its amphiphilic nature, with hydrophilic and hydrophobic parts, enabling it to interact with both water and oil-based substances, thus stabilizing emulsions. Due to its mild properties, it is used in products like shampoos, creams, and lotions to enhance product performance and consistency.

Chemical Structure

Citramide
Citramide
CAS#597-59-1

Theoretical Analysis

MedKoo Cat#: 145867

Name: Citramide

CAS#: 597-59-1

Chemical Formula: C6H11N3O4

Exact Mass: 189.0800

Molecular Weight: 189.17

Elemental Analysis: C, 38.10; H, 5.86; N, 22.21; O, 33.83

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Citramide;
IUPAC/Chemical Name
2-hydroxypropane-1,2,3-tricarboxamide
InChi Key
MPQPXMRGNQJXGO-UHFFFAOYSA-N
InChi Code
1S/C6H11N3O4/c7-3(10)1-6(13,5(9)12)2-4(8)11/h13H,1-2H2,(H2,7,10)(H2,8,11)(H2,9,12)
SMILES Code
NC(=O)CC(O)(CC(N)=O)C(N)=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 189.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ghosh R, Kelland MA. Nonpolymeric Citramide-Based Kinetic Hydrate Inhibitors: Good Performance with Just Six Alkylamide Groups. ACS Omega. 2022 Apr 13;7(16):13953-13962. doi: 10.1021/acsomega.2c00448. PMID: 35559148; PMCID: PMC9089363. 2: Couffin-Hoarau AC, Aubertin AM, Boustta M, Schmidt S, Fehrentz JA, Martinez J, Vert M. Peptide-poly(L-lysine citramide) conjugates and their in vitro anti- HIV behavior. Biomacromolecules. 2009 Apr 13;10(4):865-76. doi: 10.1021/bm801376v. PMID: 19296658. 3: Colombo PE, Boustta M, Poujol S, Pinguet F, Rouanet P, Bressolle F, Vert M. Biodistribution of doxorubicin-alkylated poly(L-lysine citramide imide) conjugates in an experimental model of peritoneal carcinomatosis after intraperitoneal administration. Eur J Pharm Sci. 2007 May;31(1):43-52. doi: 10.1016/j.ejps.2007.02.004. Epub 2007 Feb 20. PMID: 17383164. 4: Gautier S, Boustta M, Vert M. Alkylated poly(L-lysine citramide) as models to investigate the ability of amphiphilic macromolecular drug carriers to physically entrap lipophilic compounds in aqueous media. J Control Release. 1999 Aug 5;60(2-3):235-47. doi: 10.1016/s0168-3659(99)00079-6. PMID: 10425329. 5: Gac S, Coudane J, Boustta M, Domurado M, Vert M. Synthesis, characterisation and in vivo behaviour of a norfloxacin-poly(L-lysine citramide imide) conjugate bearing mannosyl residues. J Drug Target. 2000;7(5):393-406. PMID: 10721801. 6: Gac-Breton S, Coudane J, Boustta M, Vert M. Norfloxacin-poly(L-lysine citramide imide) conjugates and structure-dependence of the drug release. J Drug Target. 2004 Jun;12(5):297-307. doi: 10.1080/10611860410001724477. PMID: 15512781. 7: Abdellaoui K, Boustta M, Morjani H, Manfait M, Vert M. Uptake and intracellular distribution of 4-aminofluorescin-labelled poly(L-lysine citramide imide) in K562 cells. J Drug Target. 1998;5(3):193-206. doi: 10.3109/10611869808995874. PMID: 9606009. 8: Vert M. Not any new functional polymer can be for medicine: what about artificial biopolymers? Macromol Biosci. 2011 Dec 8;11(12):1653-61. doi: 10.1002/mabi.201100224. Epub 2011 Nov 3. PMID: 22052691. 9: Leclercq L, Morvan M, Koch J, Neusüß C, Cottet H. Modulation of the electroosmotic mobility using polyelectrolyte multilayer coatings for protein analysis by capillary electrophoresis. Anal Chim Acta. 2019 May 30;1057:152-161. doi: 10.1016/j.aca.2019.01.008. Epub 2019 Jan 18. PMID: 30832914. 10: Etrych T, Leclercq L, Boustta M, Vert M. Polyelectrolyte complex formation and stability when mixing polyanions and polycations in salted media: a model study related to the case of body fluids. Eur J Pharm Sci. 2005 Jun;25(2-3):281-8. doi: 10.1016/j.ejps.2005.03.005. Epub 2005 Apr 14. PMID: 15911224. 11: Colombo PE, Boustta M, Poujol S, Jarlier M, Bressolle F, Teulon I, Ladjemi MZ, Pinguet F, Rouanet P, Vert M. Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer. Gynecol Oncol. 2011 Sep;122(3):632-40. doi: 10.1016/j.ygyno.2011.05.032. Epub 2011 Jun 12. PMID: 21665252. 12: Leclercq L, Boustta M, Rixte J, Vert M. Degradability of poly(L-lysine) and poly(DL-aminoserinate) complexed with a polyanion under conditions modelling physico-chemical characteristics of body fluids. J Colloid Interface Sci. 2010 Oct 15;350(2):459-64. doi: 10.1016/j.jcis.2010.07.015. Epub 2010 Jul 13. PMID: 20673906. 13: Samad A, Khan AA, Sajid M, Zahra R. Assessment of biofilm formation by pseudomonas aeruginosa and hydrodynamic evaluation of microtiter plate assay. J Pak Med Assoc. 2019 May;69(5):666-671. PMID: 31105285. 14: Abdellaoui K, Boustta M, Vert M, Morjani H, Manfait M. Metabolite-derived artificial polymers designed for drug targeting, cell penetration and bioresorption. Eur J Pharm Sci. 1998 Jan;6(1):61-73. doi: 10.1016/s0928-0987(97)00069-9. PMID: 16256709. 15: Minati L, Antonini V, Torrengo S, Serra MD, Boustta M, Leclercq X, Migliaresi C, Vert M, Speranza G. Sustained in vitro release and cell uptake of doxorubicin adsorbed onto gold nanoparticles and covered by a polyelectrolyte complex layer. Int J Pharm. 2012 Nov 15;438(1-2):45-52. doi: 10.1016/j.ijpharm.2012.08.057. Epub 2012 Sep 7. PMID: 22959992. 16: Leclercq L, Boustta M, Vert M. A physico-chemical approach of polyanion- polycation interactions aimed at better understanding the in vivo behaviour of polyelectrolyte-based drug delivery and gene transfection. J Drug Target. 2003 Apr;11(3):129-38. doi: 10.1080/1061186031000150287. PMID: 13129823. 17: Leclercq L, Cottet H. Fast characterization of polyelectrolyte complexes by inline coupling of capillary electrophoresis to Taylor dispersion analysis. Anal Chem. 2012 Feb 7;84(3):1740-3. doi: 10.1021/ac203208k. Epub 2012 Jan 20. PMID: 22263867.